Following consideration of a second resubmission, the Scottish Medicines Consortium (SMC) does not recommend the use of ranolazine (Ranexa®) within NHS Scotland as an add-on therapy for the symptomatic treatment of patients with stable angina pectoris who are inadequately controlled or intolerant to first-line antianginal therapies (such as beta-blockers and/or calcium antagonists).

The drug advice summarises the efficacy, safety and cost-effectiveness data submitted by the company and considered by the Committee (please see the link below for details).  This notes that the addition of ranolazine to standard doses of antianginal drugs resulted in a modest increase in exercise duration at trough drug levels compared with placebo after 12 weeks treatment.  The submitting company did not however present a sufficiently robust clinical and economic case to gain acceptance by SMC.